Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638134 | 0.85 | HSD17B10 (0.49) | HSD17B10MAPK1RAB9ANPC1KDM4E | |
| SCHEMBL13058928 | 0.82 | DAO (0.49) | HSD17B10RAB9ANPC1KDM4EHTT | |
| SCHEMBL1029180 | 0.79 | HSD17B10 (1.00) | HSD17B10MAPK1RAB9ANPC1HTT | |
| SCHEMBL6267072 | 0.78 | HSD17B10 (0.73) | HSD17B10MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7405579 | 0.77 | CYP1A2 (0.56) | DAOCYP1A2CYP2D6CHRNA7CHRNB2 | |
| SCHEMBL3419445 | 0.77 | CYP1A2 (0.56) | HSD17B10CYP1A2CYP3A4CYP2D6CHRNA7 | |
| SCHEMBL14594941 | 0.77 | SMN1; SMN2 (0.52) | MAPK1RAB9ANPC1KDM4EHTT | |
| SCHEMBL6638041 | 0.75 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2USP2DAO | |
| SCHEMBL1520446 | 0.75 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2USP2DAO | |
| SCHEMBL8776813 | 0.74 | TSHR (0.61) | HSD17B10MAPK1RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923953-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2020168358-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-20 | — | — | WO | claimed |
| US-20200253994-A1 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-13 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3923953-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2020168358-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | HSD17B10 3826/4885MAPK1 4783/4885RAB9A 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.